Atom Investors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Atom Investors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.25M	Sell	13,474 -2,670	-17%	-$585K	0.29%	66
2026 Q1	$3.05M	Buy	+16,144	New	+$2.82M	0.22%	153
2021 Q3	–	Sell	-12,093	Closed	-$2.15M	–	346
2021 Q2	$2.15M	Buy	12,093 +6,169	+104%	+$1.07M	0.27%	70
2021 Q1	$974K	Sell	5,924 -31,531	-84%	-$5.19M	0.16%	110
2020 Q4	$6.18M	Sell	37,455 -52,175	-58%	-$7.77M	0.62%	44
2020 Q3	$12.8M	Sell	89,630 -13,614	-13%	-$1.69M	1.22%	17
2020 Q2	$11.4M	Buy	103,244 +68,877	+200%	+$7.62M	0.74%	16
2020 Q1	$3.43M	Buy	+34,367	New	+$4.44M	0.3%	83
2019 Q4	–	Sell	-35,686	Closed	-$4.57M	–	271
2019 Q3	$4.57M	Buy	35,686 +23,871	+202%	+$3.2M	0.31%	105
2019 Q2	$1.68M	Buy	+11,815	New	+$1.59M	0.11%	208

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Atom Investors's JAZZ Position: Q2 2026 in Review

Atom Investors reduced its Jazz Pharmaceuticals (JAZZ) stake by 17% in Q2 2026, selling an estimated $585K and leaving 13,474 shares worth $3.25M. The position accounts for 0.29% of the portfolio, ranked #66.

Atom Investors first reported a position in JAZZ in Q2 2019 and has held it in 10 quarters since. The position peaked at $12.8M in Q3 2020. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Atom Investors held 13,474 shares of Jazz Pharmaceuticals worth $3.25M as of Q2 2026.
Atom Investors sold 2,670 Jazz Pharmaceuticals shares in Q2 2026, an estimated $585K.
Jazz Pharmaceuticals made up 0.29% of Atom Investors's portfolio in Q2 2026, its #66 holding.
Atom Investors first reported a position in Jazz Pharmaceuticals in Q2 2019 and has held it in 10 quarters since.
Atom Investors's Jazz Pharmaceuticals position peaked at $12.8M in Q3 2020.
646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Atom Investors's 13F filing for Q2 2026, filed 14 Aug 2026.